Clinical Trials

Protocol No.: 20020121

• Title: Study of the Effects of Neutropenia on Patient Reported Outcomes during Chemotherapy with or without Neulasta in Subjects with Advanced NSCLC
• Status: Completed 2005 (4 patients)

Protocol No.: 20170596

• Title: An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
• Status: Open (1 patient)

Protocol No.: 20170758

• Title: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN
• Status: Open (14 patients)

Protocol No.: APTO-CG-806-01

• Title: A Phase 1 a/b trial to evaluate the safety and tolerability of CG-806 in patients with CLL/SLL or Non-Hodgkin’s Lymphomas
• Status: Open May 2019

Protocol No.: AST-CP-US

• Title: A MultiCenter Study for the Collection of Biofluids for Genomics, Proteomics and Biomarker Research from Subjects Identified with Specific Diseases and from Subjects Identified with No Specific Diseases.
• Status: Open since July 2015 (190 patients)

Protocol No.: D4191C00068

• Title: An Open-Label, Mutli-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG)
• Status: Open since 2017

Protocol No.: BDX-00146 (INSIGHT)

• Title: An Observational Study Assessing the Clinical Effectiveness of VeriStrat and the Validation of Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer.
• Status: Completed (21 patients)

Protocol No.: ACE-536-MDS-002

• Title: Comparison of Tissue Biomarker Testing Turn Around Time between Standard Of Care and the Idylla Platform in Metastatic Colorectal Cancer Patients
• Status: Completed April 2019 (5 patients)

Protocol No.: S0702

• Title: Observational Study of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Bone Disease Starting Zoledronic Acid
• Status: Completed 2012 (12 patients)

Protocol No.: B42

• Title: Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
• Status: Completed 2013 (3 patients)

Protocol No.: SWOG S0307

• Title: Phase III Trial of Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer: Comparison of Toxicities and Patient-Stated Preference For Oral Versus Intravenous Delivery
• Status: Completed 2013 (5 patients)

Protocol No.: ACE-536-MDS-002

• Title: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions.
• Status: Open since August 2018

Protocol No.: PGT 302

• Title: PGT 302: CT 2103 v/s Docetaxel in Non-Small Cell Lung Cancer 2004
• Status: Completed 2004 (4 patients)

Protocol No.: NEPA-17-05

• Title: A multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group phase 3b study to assess the safety and to describe the efficacy of IV fosnetupitant/palonosetron (260 mg/0.25 mg) combination (IV NEPA FDC) compared to oral netupitant/palonosetron (300 mg/ 0.5 mg) combination (Akynzeo®) for the prevention of chemotherapy-induced nausea and vomiting in initial and repeated cycles of anthracycline-cyclophosphamide (AC) chemotherapy in women with breast cancer
• Status: Completed February 2019 (4 patients)

Protocol No.: AAPAC2013-01

• Title: Compared Efficacy and Safety of A Single Subcutaneous Dose of SUSTOL (10 mg granisetron) in Combination with fosaprepitant 150 mg IV, Dexamethasone, and ondansetron Placebo to ondansetron 0.15 mg/Kg IV in Combination with fosaprepitant 150 Mg IV, Dexamethasone, And SUSTOL Placebo Administered Prior To HEC as Defined by 2011 ASCO emetogenicity Classifications
• Status: Completed August 2015

Protocol No.: HTX-023-C2015-401

• Title: An Observational Study of the Real World Effectiveness of Palonosetron HCL (IV injection) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy Treatment According to the 2011 ASCO Antiemetic Guidelines
• Status: Completed December 2015

Protocol No.: INCB-MA-PV-401

• Title: Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices.
• Status: Open since July 2015 (38 patients)

Protocol No.: INCB-MA-MF-401

• Title: Prospective, Longitudinal, Non-interventional study of disease burden and treatment of patients with low-risk Myelofibrosis(MF) or High Risk Essential Thrombocythemia(ET) or ET patients receiving ET-directed therapy.
• Status: Open since November 2016 (closed date) (34 patients)

Protocol No.: INCB 18424-272

• Title: A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea
• Status: Open since 2017

Protocol No.: INI-001

• Title: Prospective observational multicenter study to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced non-small cell lung cancer.
• Status: Closed (10 patients)

Protocol No.: 1VIT14039

• Title: “IRON CLAD: Can Iron Lessen Anemia Due to cancer and chemotherapy: A multi-center, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose injection)”
• Status: Completed August 2018 (6 patients)

Protocol No.: ONC-010 EXET

• Title: Endopredict® Extended Endocrine Trial(EXET): A prospective registry to evaluate the Impact the EndoPredict in decision regarding extended endocrine Treatment
• Status: Ongoing (29 patients)

Protocol No.: CSEG101A2202

• Title: A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis
• Status: Closed Enrollment (3 patients)

Protocol No.: CLEE011A2404

• Title: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
• Status: Closed Enrollment (1 patient)

Protocol No.: 866385

• Title: On-site Physician-patient communication research study for patients diagnosed with Sickle cell Disease or Low to Medium risk Myelodysplastic Syndrome.
• Status: Completed September 2015

Protocol No.: 09-08

• Title: Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
• Status: Completed February 2019

Protocol No.: PR 02-27-015

• Status: Completed 2004 (17 patients)

Protocol No.: A5481082

• Title: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study (NIS)
• Status: Open (8 patients)

Protocol No.: PCYC-1134M

• Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia
• Status: Open since 2015 (20 patients)

Protocol No.: PRO-1676

• Title: ADOPTR: A Digimed Oncology PharmacoTherapy Registry
• Status: Open since 2019 (1 patient)

Protocol No.: G029436

• Title: A phase III Open Label Randomized Study of Atezolizumab in combination with Carboplatin+Paclitaxel with or without Bevacizumab in Chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer
• Status: Completed April 2017

Protocol No.: Seer-020102

• Title: A prospective blood sample collection study to evaluate a panel of protein-based biomarkers
• Status: Open since 2019 (7 patients)

Protocol No.: SPI-GCF-301

• Title: Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide. (TC) (ADVANCE)
• Status: Completed November 2018 (10 Patients)

Protocol No.: SPI-POZ-201

• Title: “A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) Who have received Prior HER2 Regimens for MBC.”
• Status: Completed November 2018

Protocol No.: SPI-GCF-302

• Title: Randomized, Open-label, Active-Control Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)
• Status: Open since June 2016 (4 Patients)
  Closed enrollment

Protocol No.: TL32711-RAN-0094-PTL

• Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
• Status: Completed January 2016

Protocol No.: 99311

• Title: Randomized Placebo-controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation among Cancer Survivors
• Status: Completed 2013 (15 patients)